KevinRBoothMD
Neurology • Collegeville, PASleep Medicine, Neurodegenerative
Director/Clinical Scientist Global Product Development Pfizer
Dr. Booth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
500 Arcola Rd.
F-3231
Collegeville, PA 19426
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Neurology, 1986 - 1989- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHInternship, Internal Medicine, 1985 - 1986
University of Michigan Medical SchoolClass of 1985
Certifications & Licensure
PA State Medical License 2016 - 2024- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 35 citationsLong-Term Extensions of Randomized Vaccination Trials of ACC-001 and QS-21 in Mild to Moderate Alzheimer's Disease.Michael Hüll, Carl H. Sadowsky, Heii Arai, Ghislaine Le Prince Leterme, Ann R Holstein
Current Alzheimer Research. 2017-06-30 - 25 citationsLong-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.Adrian Ivanoiu, Jérémie Pariente, Kevin Booth, Kasia Lobello, Gerald Luscan
Alzheimer's Research & Therapy. 2016-06-23 - 198 citationsBapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.Rik Vandenberghe, Juha O. Rinne, Mercè Boada, Sadao Katayama, Philip Scheltens
Alzheimer's Research & Therapy. 2016-05-12
Industry Relationships
- Director, Pfizer, Inc.Clinical Development clinician in neuropsychiatric and immunologic diseasesDisclosure: Employee of Pfizer, Inc.2005 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
